Navigation Links
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
Date:10/25/2010

VIENNA, Oct. 25 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

In the randomized, controlled Phase II clinical trial (33 sites in 8 countries), about 400 mechanically ventilated intensive care patients, who are at particular high risk of acquiring severe and often life-threatening forms of Pseudomonas aeruginosa infections, such as Ventilator-Associated Pneumonia (VAP), sepsis or soft tissue infection were vaccinated on days zero and seven in four treatment groups  receiving 100 or 200mcg alum-adjuvanted vaccine, 100mcg non-adjuvanted vaccine or alum as placebo control.

The primary endpoint of the study was met in that all vaccine groups showed good seroconversion rates (65 - 81%) with IgG antibody Geometric Mean Titers (GMTs) (995-2117 ELISA units/ml). There were no significant differences in treatment emergent adverse events between the treatment arms and local and systemic tolerability appeared to be good, as far as assessable in this study population. The number and nature of reported drug related adverse events does not raise any safety concern and has been confirmed earlier by a Data Safety Monitoring Board (DSMB) based on interim data.

Secondary immunogenicity endpoints were also met in this study and included IgG response assessed seven times over a period of 90 days, measurement of functional antibody activity by opsonophagocytosis assay, and measurement of antibody avidity.

Overall robust immunogenicity following second vaccination was observed in all vaccine groups. A dose-response could be observed, whereas alum did not show a clear immune-enhancing effect. Antibody avid
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
2. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
3. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
4. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
5. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
8. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
9. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 ... not-for-profit provider of home health care, hospice and palliative ... Bank to ring the Opening Bell yesterday at the ... a New Jersey philanthropist and social entrepreneur to care ... VNA Health Group has always worked to meet the ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker ... National Fire Protection Association (NFPA), a recognized international ... in a Memorandum of Understanding signed by both ... other stakeholders with information, guidance and access to ... and safety of workers in ready-made garment (RMG) ...
Breaking Medicine News(10 mins):Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... June 22 With the outbreak of H1N1 influenza in ... vaccine, which can effectively prevent the disease from spreading. The ... become a hot topic around the world. In fact, the ... industry in China and globally for quite some time now. ...
... Families by Killing 99.9% of Illness-Causing Bacteria on Soft Surfaces , ... be the only ones getting comfy and cozy on the sofa. ... home can harbor thousands of bacteria. In fact, if fabric ... on them for months.(1) , , Families now have ...
... has found that Caucasians are much more likely than people ... soft tissue cancer called Ewing,s sarcoma. In addition, among Caucasians ... women. Published in the August 1, 2009 issue of ... the study indicates that examining the gender and racial differences ...
... - Donating blood today will help save lives , ... and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn / ... donate blood in advance of the July 4th holiday weekend. ... "trauma season" for most emergency rooms. According to the Centers ...
... transplant recipients to suppress their immune systems, has a paradoxical ... Emory Vaccine Center have discovered. In experiments conducted in ... memory CD8 T cells, which enable the immune system to ... second encounter. The results were published online ahead of ...
... Pick shades with UV protection, and wear them a ... News) -- Price and style -- not protection from ... considerations when buying sunglasses, a new survey has found. ... the American Optometric Association, which conducted the survey. , ...
Cached Medicine News:Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 2Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 3Health News:Harmful Bacteria May Hide on Soft Surfaces in Your Home 2Health News:Caucasians are at higher risk of developing Ewing's sarcoma than other races 2Health News:Give Life for the Fourth of July 2Health News:Give Life for the Fourth of July 3Health News:Transplant drug stimulates immune memory 2Health News:Not All Sunglasses Are Created Equal 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: